Last reviewed · How we verify
NCT05319028
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial testing Mivavotinib in Non-GCB/ABC Diffuse Large B-Cell Lymphoma in 2 participants. Terminated before completion.
24 February 2023
Quick facts
| Lead sponsor | Calithera Biosciences, Inc |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 23 June 2022 |
| Primary completion | 24 February 2023 |
| Estimated completion | 24 February 2023 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Mivavotinib — full drug profile →
Conditions studied
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma — all drugs for Non-GCB/ABC Diffuse Large B-Cell Lymphoma →
- With and Without MyD88 and/or CD79B Mutations — all drugs for With and Without MyD88 and/or CD79B Mutations →
Sponsor
Calithera Biosciences, Inc — full company profile →
Who can join
Adults 18 to 100, any sex, with Non-GCB/ABC Diffuse Large B-Cell Lymphoma or With and Without MyD88 and/or CD79B Mutations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05319028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mivavotinib
Trials testing the same drug.
- NCT03756818 — TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors · Phase 1 · completed
Other Calithera Biosciences, Inc trials
Trials by the same sponsor.
- NCT04698681 — NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial · terminated
- NCT04607512 — Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects · Phase 1 · completed
- NCT04540965 — Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects · Phase 1 · completed
- NCT04265534 — KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamo · Phase 2 · terminated
- NCT04279769 — Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05319028 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Calithera Biosciences, Inc
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05319028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing